Adaptations of Cellular Growth and Differentiation Hyperplasia

Slide 1 · Hyperplasia

Adaptations of cellular growth and differentiation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Define hyperplasia in terms of cell number and proliferative capacity.

Distinguish physiologic hormonal and compensatory hyperplasia from pathologic responses.

Explain the major breast, liver, marrow, endometrial, prostatic, and viral examples.

Relate regulated proliferation to reversibility and potential cancer risk.

Slide 3 · Cellular adaptations respond to a stimulus

A stimulus arises

Physiologic demand, cell loss, or abnormal growth signals

Responsive cells react

Cells that can divide enter a proliferative response

Tissue cell number rises

An expanded population changes the tissue mass or capacity

Hyperplasia describes how a tissue grows: Through more cells.

Slide 4 · Hyperplasia increases cell number

Before stimulus

After stimulus

Within a comparable field, the number of cells increases

Schematic — conceptual comparison; Not a histologic specimen

Slide 5 · Hyperplasia and hypertrophy are distinct

Feature

Hyperplasia

Hypertrophy

Primary change

Increased cell number

Increased cell size

Requires cell division?

Yes — cells must be capable of dividing

No — cells can enlarge without dividing

Can coexist?

Yes

Yes

Source example

Breast glandular epithelium

Breast epithelial cell enlargement

An enlarged organ does not identify which cellular adaptation produced the growth.

Slide 6 · Proliferative capacity is a prerequisite

Hyperplasia requires tissue cells with the ability to divide.

The same stimulus may produce different outcomes in different tissues.

Tissues with minimal division may increase cell mass predominantly by hypertrophy.

Interpret the adaptive response in relation to the cells involved.

Cell type limits the possible growth response.

Slide 7 · Cell number versus cell size: Visual test

Same population of cells

Enlarged individual cells

Cell number remains similar; Individual cells enlarge

Schematic — conceptual comparison; Not a histologic specimen

Slide 8 · Hyperplasia and hypertrophy often coexist

Both responses may be triggered by the same external stimulus.

One tissue may contain more cells and larger cells simultaneously.

Breast glandular epithelium during normal hormonal adaptation illustrates this combination.

The relative contribution varies by tissue and stimulus.

Do not force a single-mechanism label on mixed adaptive growth.

Slide 9 · Two broad categories of hyperplasia

Physiologic

Pathologic

Appropriate hormonal or growth-factor action

Increased functional capacity

Compensation for damage or resection

Excessive or inappropriate hormonal / growth-factor action

Abnormal enlargement of responding cell populations

May stabilize or regress when the stimulus is removed

“Pathologic” identifies an abnormal stimulus-response setting, not necessarily cancer.

Slide 10 · The organizing questions for any example

Stimulus

What is demanding extra tissue, or driving proliferation?

Responding cell

Which target cells have proliferative capacity?

Consequence

Is the increase adaptive, symptomatic, or potentially risky?

Identify stimulus → responsive cell population → functional consequence.

Slide 11 · What is—and is not—implied by hyperplasia

The term describes a quantitative change in the cellular population.

Its causes and consequences depend on the specific organ and stimulus.

Hyperplasia can occur during normal development or tissue compensation.

A diagnosis of hyperplasia alone does not establish malignancy.

A morphologic response must be interpreted in its biologic context.

Slide 12 · A brief mechanism bridge

Hormone or growth factor

A proliferative signal acts on a responsive cell

Cell activation

Growth-related signaling promotes cell-cycle activity

Cell proliferation

Division increases the number of tissue cells

More detailed signaling and stem-cell biology belong to the next Robbins topic.

Slide 13 · Physiologic hyperplasia: Three exemplars

Breast

Hormonal stimulation

Increased glandular epithelial cells

Often combined with hypertrophy

Liver

Partial tissue loss

Proliferation of remaining cells

Recovery toward original size

Bone marrow

Deficiency of mature blood cells

Feedback growth-factor signaling

More blood-cell progenitors

Physiologic hyperplasia can be hormonal or compensatory.

Slide 14 · Hormonal hyperplasia of the breast

Female breast glandular epithelium is a hormone-responsive tissue.

At puberty, glandular epithelial cells proliferate.

During pregnancy, glandular epithelial proliferation is again prominent.

The response supports enlargement of the hormone-sensitive organ.

The cells undergoing hyperplasia are specified: Glandular epithelial cells.

Slide 15 · Puberty: A physiologic proliferative response

Hormonal context

Normal maturation creates a demand for breast growth

Glandular epithelium

Epithelial cells capable of dividing respond

More glandular cells

The breast undergoes physiologic hyperplasia

This is a normal developmental stimulus, not an autonomous lesion.

Slide 16 · Pregnancy: Hormonal adaptation of the breast

Pregnancy

Hormonal conditions change tissue demand

Epithelial proliferation

Glandular epithelial cell number increases

Tissue adaptation

Growth occurs together with cellular enlargement

One stimulus can lead to hyperplasia plus hypertrophy.

Slide 17 · The breast illustrates mixed growth mechanisms

Cell-number change

Cell-size change

Additional glandular epithelial cells

Requires competent proliferation

Defines hyperplasia

Enlargement of epithelial cells

Can occur concurrently

Defines hypertrophy

Describe both alterations where the source documents both.

Slide 18 · Case: Glandular breast growth in pregnancy

Clinical or experimental scenario

During pregnancy, the glandular epithelium of the breast expands and individual epithelial cells enlarge.

Reason through

Which component is hyperplasia?

Which component is hypertrophy?

Why is the overall response physiologic?

Slide 19 · Reasoning: Pregnancy-related breast growth

Explanation

More glandular epithelial cells = hyperplasia.

Larger glandular epithelial cells = hypertrophy.

The stimulus arises in a normal hormonal setting to increase organ capacity.

The process classification depends on both mechanism and context.

Slide 20 · Liver regeneration is compensatory hyperplasia

Partial removal of the liver reduces the remaining organ mass.

Residual cells can proliferate to replace lost tissue capacity.

The remaining liver can grow back toward its original size.

This is a classic model of compensatory hyperplasia.

Slide 21 · Partial hepatectomy: The adaptive sequence

Resection

A portion of the liver is removed

Proliferation

Remaining liver cells respond and divide

Recovery

The residual liver increases in size

Compensation is driven by cell proliferation, not replacement of the removed lobe as a discrete new lobe.

Slide 22 · What the donor-liver example demonstrates

An organ can recover lost mass by proliferation of surviving cells.

The stimulus follows removal of part of the organ, not an abnormal endocrine excess.

Growth is an adaptive response to diminished tissue capacity.

Partial hepatectomy models have informed understanding of regeneration.

Tissue loss can trigger a regulated proliferative program.

Slide 23 · Liver-cell proliferation: Source-level mechanism

Partial resection

Remaining tissue experiences a regenerative demand

Growth factors

Liver-derived factors engage receptors on survivors

Hepatocyte response

Signaling pathways stimulate cell proliferation

The neighboring topic expands this mechanistic sequence.

Slide 24 · How new liver cells may arise

Surviving mature cells

Tissue stem cells

Residual hepatocytes may proliferate

Growth factors stimulate replication

Major explanation in partial hepatectomy

May contribute when hepatocyte division is impaired

Described for some hepatitic injury settings

A conditional alternative, not the default for every resection

Regeneration need not always recruit the same cellular source.

Slide 25 · Regeneration is not unrestricted growth

Hyperplasia answers a specific tissue-loss stimulus.

The organ-size response is described as recovery toward the original size.

No autonomous neoplastic process is required to explain the response.

An adaptive increase in cell number can be substantial without being malignant.

Slide 26 · Case: Living-donor liver remnant

Clinical or experimental scenario

After donation of part of a liver, the remaining hepatic tissue enlarges in the course of regeneration.

Reason through

What adaptive process accounts for additional liver cells?

What stimulus initiates this response?

Which possible cell populations can supply new cells?

Slide 27 · Reasoning: Liver remnant

Explanation

Compensatory hyperplasia follows loss of tissue mass.

Growth-factor signaling promotes proliferation of surviving hepatocytes.

When mature-cell proliferative capacity is compromised, tissue stem cells may contribute.

Identify the compensatory trigger before describing the mechanism.

Slide 28 · Bone marrow has substantial adaptive capacity

Production of mature blood cells is linked to demand.

Deficiency of mature circulating blood cells triggers compensatory responses.

Hematopoietic progenitor populations can expand rapidly.

This capacity is a physiologic example of hyperplasia.

Slide 29 · Blood loss can stimulate marrow hyperplasia

Acute bleeding

Circulating red blood cells are lost

Feedback response

Erythropoietin signaling is activated

Marrow expansion

Red cell progenitors proliferate to raise output

The expanded marrow precursor pool helps restore red-cell production.

Slide 30 · Hemolysis can stimulate the same response

Premature red-cell breakdown

Circulating erythrocytes are lost early

Feedback response

Erythropoietin-related signaling increases

Red-cell production

More progenitors support compensatory output

Distinct causes of red-cell deficiency may converge on marrow hyperplasia.

Slide 31 · Erythropoietin links demand to proliferation

Erythropoietin is a growth factor in erythroid feedback.

Feedback loops are activated by bleeding or hemolysis.

Growth of red-cell progenitors increases the capacity for erythropoiesis.

The biologic target is the precursor population, not the mature circulating erythrocyte.

Slide 32 · The feedback logic of erythroid hyperplasia

Red-cell deficit

Loss or destruction lowers mature cell availability

Growth-factor signal

Erythropoietin-dependent feedback is activated

Precursor proliferation

An expanded erythroid precursor population

Greater output

More red cells can be produced

Compensatory marrow growth responds to a deficiency in the mature cell compartment.

Slide 33 · A source-reported quantitative example

Red-cell production can increase as much as eightfold.

This occurs when erythropoietin-related feedback stimulates erythroid progenitors.

The statement illustrates substantial reserve in hematopoietic responses.

It is not presented as the response magnitude in every patient.

“As much as” identifies a potential capacity, not an expected fixed response.

Slide 34 · Hemorrhage and hemolysis: Same marrow principle

Feature

Acute blood loss

Premature red-cell breakdown

Primary problem

Mature red cells are lost externally

Mature red cells are destroyed early

Compensation

Erythropoietin feedback

Erythropoietin feedback

Response population

Erythroid progenitors

Erythroid progenitors

Adaptation

Marrow hyperplasia

Marrow hyperplasia

Classify by the proliferating compartment rather than by the trigger alone.

Slide 35 · Case: Increased marrow erythropoiesis

Clinical or experimental scenario

Following acute hemorrhage, the hematopoietic tissue expands its erythroid progenitor population.

Reason through

Which tissue exhibits hyperplasia?

Which population increases in number?

Why is this a compensatory rather than an autonomous response?

Slide 36 · Reasoning: Marrow after hemorrhage

Explanation

The adaptive tissue is hematopoietic bone marrow.

The expanding cells are red-cell progenitors.

Feedback through erythropoietin links the proliferative response to red-cell deficiency.

Blood-cell deficits can be compensated by increased production at the precursor stage.

Slide 37 · Physiologic and pathologic growth signals

Appropriate stimulus

Excess or inappropriate stimulus

Normal hormonal demand

Functional capacity requirement

Loss of tissue or mature cells

Hormonal imbalance

Abnormal action of growth signals

Virally perturbed proliferation control

A shared proliferative mechanism can have different biologic meanings.

Slide 38 · Pathologic hyperplasia still requires signals

Most pathologic examples reflect excessive or inappropriate hormonal or growth-factor action.

Target cells retain the ability to proliferate in response.

The increased cell number is abnormal in context.

Abnormal proliferation need not be autonomous cancer growth.

Abnormal stimulation is not synonymous with malignant transformation.

Slide 39 · Hormonal imbalance can cause pathologic growth

Imbalanced regulation

A proliferative hormonal influence predominates

Target-cell response

Responsive epithelial cells divide

Hyperplasia

An abnormal increase in the target cell population

The identity of the hormone and target tissue changes by organ.

Slide 40 · Why pathologic hyperplasia remains controlled

The source distinguishes hyperplasia from cancerous, unrestrained growth.

Removal of abnormal hormonal stimulation may permit regression.

Alternatively, the hyperplastic lesion may stabilize.

Reversibility is an important biologic distinction, not a universal treatment guarantee.

An abnormal cell population can remain dependent on an external stimulus.

Slide 41 · Removing a growth stimulus

Active stimulation

Hormones or growth factors maintain proliferation

Signal removed

The excessive stimulus is eliminated

Possible outcome

Hyperplasia regresses or stabilizes

The response to withdrawal helps distinguish stimulus dependence from autonomous growth.

Slide 42 · Normal endometrium undergoes cyclic proliferation

After menstruation, endometrial proliferation increases rapidly.

Pituitary hormones and ovarian estrogen support this response.

The growth phase is regulated within the menstrual cycle.

Normal regulation includes an eventual halt to proliferation.

Slide 43 · Normal endometrial proliferation has a brake

Following menstruation

Rapid endometrial proliferation

Estrogen action

Endometrial gland proliferation

Rising progesterone

Proliferation is halted

Estrogen-related proliferation is physiologic when appropriately regulated.

Slide 44 · Progesterone restrains endometrial proliferation

The rising level of progesterone normally halts proliferation.

This restraint about 10–14 days before the end of the menstrual period.

A normal proliferative burst therefore does not continue unchecked.

The estrogen–progesterone balance is central to this example.

Failure of restraint is a route to pathologic hyperplasia.

Slide 45 · Endometrial hyperplasia: The causal sequence

Hormonal imbalance

Absolute or relative estrogen predominance

Glandular proliferation

Endometrial glands receive excessive proliferative stimulation

Endometrial hyperplasia

An abnormal increase in glandular cells

The target population is the endometrial glandular epithelium.

Slide 46 · Absolute versus relative estrogen excess

Absolute increase

Relative predominance

An increase in estrogen amount can enhance proliferative drive

Regulatory balance becomes abnormal

Estrogen action may be excessive relative to progesterone restraint

The relationship between signals matters

Hormonal balance—not merely one isolated absolute level—determines the proliferative context.

Slide 47 · Why the endometrial glands expand

Estrogen stimulates endometrial glandular proliferation.

Normal progesterone-associated restraint is insufficient or disrupted.

Prolonged proliferative signaling increases the number of glandular cells.

This is abnormal hormone-induced hyperplasia.

Slide 48 · Endometrial gland proliferation: Schematic

Regulated glandular growth

Hyperplastic glandular growth

Conceptual illustration: Increased glandular epithelial proliferation, not a diagnostic micrograph.

Schematic — no histologic grading or diagnostic architecture is implied

Slide 49 · Clinical consequence: Abnormal uterine bleeding

Endometrial hyperplasia is a common cause of abnormal uterine bleeding.

The proliferating glandular compartment is hormonally responsive.

The clinical manifestation must be understood alongside hormonal context.

The source does not supply a diagnostic algorithm or quantitative bleeding risk here.

A cell-growth mechanism can have a direct clinical expression.

Slide 50 · Endometrial case: Link stimulus to symptom

Estrogen predominance

Altered estrogen–progesterone balance

Glandular hyperplasia

Persistent glandular proliferation

Clinical presentation

Abnormal uterine bleeding

The chain is causal at source level; It is not a complete differential diagnosis for bleeding.

Slide 51 · Endometrial hyperplasia and cancer risk

Hyperplasia itself is not synonymous with carcinoma.

Increased cell division can provide opportunities for genetic aberrations.

The source identifies endometrial hyperplasia as associated with increased cancer risk.

This association should not be interpreted as inevitable malignant progression.

Risk elevation is not a diagnosis of malignancy.

Slide 52 · Case: Abnormal endometrial proliferation

Clinical or experimental scenario

An abnormal estrogen–progesterone balance is followed by excessive proliferation of the endometrial glands and abnormal uterine bleeding.

Reason through

Which stimulus is abnormal?

Which cells are increasing in number?

Does the term “hyperplasia” alone diagnose cancer?

Slide 53 · Reasoning: Endometrial hyperplasia

Explanation

Estrogenic proliferative influence is excessive in absolute or relative terms.

The expanding cell population is the endometrial glandular epithelium.

This remains hyperplasia; Cancer risk may be elevated, but cancer is not established.

Separate causal mechanism, clinical manifestation, and malignant potential.

Slide 54 · Benign prostatic hyperplasia is pathologic hyperplasia

The prostate is another hormone-responsive organ.

Androgen stimulation as the relevant pathologic stimulus.

The responding tissue increases its cellular population.

The example illustrates a common abnormal hyperplastic response.

The source establishes hormonal causation here, not a complete clinical BPH model.

Slide 55 · Benign prostatic hyperplasia: Source-level model

Androgenic stimulation

Hormonal signals act on the prostate

Target tissue response

A proliferative program increases tissue cells

Benign hyperplasia

Prostatic tissue enlarges in an abnormal setting

Benign and pathologic are compatible terms: Abnormal response, not malignant cancer.

Slide 56 · Endometrium and prostate: What differs?

Endometrium

Prostate

Hormonal balance: Estrogen versus progesterone

Hyperplasia of endometrial glands

Abnormal uterine bleeding is cited

Hormonal influence: Androgens

Benign prostatic hyperplasia is cited

Detailed symptoms are outside this source section

The common principle is hormone-associated proliferation of responsive tissue.

Slide 57 · Do not confuse benign hyperplasia with cancer

“Benign prostatic hyperplasia” names a nonmalignant hyperplastic condition.

The source describes pathologic hyperplasia as controlled and often signal dependent.

A label of pathologic hyperplasia does not by itself imply invasive neoplasia.

Cancer-associated risk statements must be organ- and lesion-specific.

Avoid transferring the risk of one hyperplastic condition to another.

Slide 58 · From regulated proliferation to potential risk

Hyperplasia

A stimulus-dependent rise in cell divisions

Additional divisions

Opportunities for genetic aberrations increase

Possible progression

Some lesions may eventually develop cancer

This is a risk framework, not an automatic progression pathway.

Slide 59 · Hyperplasia versus cancer: Source-supported distinctions

Question

Hyperplasia

Cancer

Cell growth

Increased cell number

Unrestrained proliferation is emphasized

Dependence on stimulus

Often remains hormone/growth-factor dependent

May be driven by acquired genetic changes

Reversal

May regress or stabilize if signal removed

No such general regression claim in source

Relationship

Can be a risk setting

A distinct pathologic process

“Hyperplasia” and “cancer” name different biologic states.

Slide 60 · What can be inferred about cancer risk?

The risk depends on the specific hyperplastic process.

Robbins specifically links endometrial hyperplasia with increased endometrial cancer risk.

It also notes that some papillomavirus-induced epithelial proliferations are precursors.

The excerpt does not classify every hyperplasia as premalignant.

Retain the qualifiers “some” and “risk”; Avoid deterministic language.

Slide 61 · Papillomaviruses can cause epithelial hyperplasia

Certain viral infections characteristically trigger hyperplasia.

Papillomaviruses are the example identified in the text.

They produce skin warts and several mucosal lesions.

The lesions consist of masses of hyperplastic epithelium.

Slide 62 · Papillomavirus-induced proliferative response

Viral infection

Papillomavirus affects epithelial cells

Regulatory interference

Viral factors interfere with host proliferation control

Epithelial expansion

Hyperplastic epithelium forms warts or mucosal lesions

Viral disturbance of cell-growth control is a distinct pathologic trigger.

Slide 63 · Site of viral hyperplasia

Skin

Mucosal epithelium

Papillomavirus-associated warts

Accumulations of hyperplastic epithelium

Evidence of a virus-associated proliferation response

Several mucosal lesions may occur

Epithelial hyperplasia is described

Some lesions are precursors to cancer

An etiologic stimulus may produce hyperplasia at more than one epithelial site.

Slide 64 · Not all virally induced hyperplasias are equivalent

The source states that some viral proliferations can precede cancer.

It does not say every cutaneous wart transforms.

Different lesion types require their own diagnostic context.

Maintain the distinction between epithelial overgrowth and malignant transformation.

Do not overinterpret a viral stimulus as proof of carcinoma.

Slide 65 · Three pathologic pathways to compare

Endometrium

Estrogen predominance

Glandular proliferation

Abnormal bleeding; Cancer risk noted

Prostate

Androgenic stimulation

Benign hyperplasia

Hormone-associated tissue expansion

Papillomavirus

Viral interference

Epithelial hyperplasia

Warts / mucosal lesions; Some precursors

Similar growth phenotype; Distinct stimuli and clinical implications.

Slide 66 · Physiologic examples: Trigger and response

Example

Initiating stimulus

Responding population

Breast growth

Puberty / pregnancy hormones

Glandular epithelium

Residual liver

Partial removal of liver

Surviving hepatocytes; possibly stem cells when capacity impaired

Marrow response

Bleeding or hemolysis

Red-cell progenitors

The term “hyperplasia” applies to different cell populations across organs.

Slide 67 · Pathologic examples: Trigger and consequence

Example

Stimulus

Consequence emphasized in Robbins

Endometrium

Absolute/relative estrogen excess

Excess glands; abnormal bleeding; increased cancer risk

Prostate

Androgen stimulation

Benign prostatic hyperplasia

Papillomavirus

Viral perturbation of growth control

Warts / mucosal lesions; some are cancer precursors

The clinical and neoplastic implications cannot be generalized across examples.

Slide 68 · A practical way to classify tissue overgrowth

First establish that cell number, rather than only cell size, has increased.

Identify the proliferating population and its capacity to divide.

Ask whether the signal is appropriate, compensatory, excessive, or virally perturbed.

Then interpret local consequences and any specifically established cancer association.

Classification requires mechanism, context, and organ specificity.

Slide 69 · Application: Match the stimulus

Clinical or experimental scenario

Consider three separate observations: Breast growth during pregnancy; Marrow erythroid expansion after hemolysis; Endometrial gland expansion under estrogen predominance.

Reason through

Which two observations are physiologic responses?

Which is pathologic hyperplasia?

Name the proliferating cell population in each.

Slide 70 · Application: Match the three examples

Explanation

Pregnancy-related breast glandular proliferation is physiologic hormonal hyperplasia.

Hemolysis-related red-cell progenitor expansion is physiologic compensatory hyperplasia.

Estrogen-predominant endometrial glandular expansion is pathologic hyperplasia.

The trigger and biologic context determine the classification.

Slide 71 · Application: Cancer-risk reasoning

Clinical or experimental scenario

A student states: “Every hyperplastic lesion is a precursor of cancer because hyperplasia increases cell division.”

Reason through

Which part of the statement is supported?

Which conclusion goes beyond the source?

Which named examples carry a stated risk association?

Slide 72 · Application: Precise cancer-risk language

Explanation

Increased division can increase opportunities for genetic aberrations.

Robbins does not state that every hyperplasia will progress to cancer.

The excerpt specifically highlights endometrial hyperplasia and some viral epithelial proliferations.

Use probabilistic risk statements, never inevitable-progression claims.

Slide 73 · Synthesis: Five defensible statements

Hyperplasia means more cells in a stimulated tissue.

Cell division competence is necessary; Hypertrophy may coexist.

Physiologic hyperplasia is hormonal or compensatory.

Most pathologic forms involve excessive/inappropriate signals; Viral control interference is another example.

Hyperplasia is distinct from cancer, although some processes elevate risk.

Slide 74 · Primary reference and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

Chapter 2: Cell Injury, Cell Death, and Adaptations; “Hyperplasia,” printed pp. 53–54.

Brief supporting mechanism explanation: “Mechanisms of Hyperplasia,” p. 54.

Original diagrams are editable schematics, not histologic or clinical specimens.